| Date | Time | Source | Headline | Symbol | Company |
| 11/24/2014 | 7:35AM | Business Wire | ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/21/2014 | 4:19PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/13/2014 | 4:28PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/07/2014 | 4:52PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/06/2014 | 9:44AM | Business Wire | ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/05/2014 | 7:41AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/05/2014 | 7:35AM | Business Wire | ARIAD Reports Third Quarter 2014 Financial Results and Development Progress | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 11/04/2014 | 7:35AM | Business Wire | ARIAD to Present at the Stifel 2014 Healthcare Conference | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/24/2014 | 4:06PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/24/2014 | 10:55AM | Business Wire | ARIAD annuncia l'adozione di un'opinione finale per Iclusig da parte del Comitato europeo per i medicinali per uso umano | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/24/2014 | 8:48AM | Business Wire | ARIAD annonce l'adoption de l'avis définitif sur l’Iclusig par le Comité des médicaments à usage humain en Europe | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/24/2014 | 8:23AM | Business Wire | ARIAD meldet Bestätigung der positiven abschließenden Stellungnahme zu Iclusig durch den Ausschuss für Humanarzneimittel i... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/24/2014 | 7:35AM | Business Wire | ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/17/2014 | 4:23PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/16/2014 | 4:26PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/15/2014 | 7:35AM | Business Wire | ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/10/2014 | 3:43PM | Business Wire | ARIAD rende nota la raccomandazione per Iclusig da parte del Comitato di valutazione dei rischi per la farmacovigilanza dell'... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/10/2014 | 10:12AM | Business Wire | Ariad annonce les recommandations du comité pour l’évaluation des risques en matière de pharmacovigilance de l’Agence ... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/10/2014 | 7:49AM | Business Wire | ARIAD erhält befürwortende Stellungnahme für Iclusig vom Beratenden Ausschuss für Risikobewertung im Bereich der Pharmako... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/10/2014 | 7:44AM | Business Wire | ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/10/2014 | 6:00AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/06/2014 | 7:35AM | Business Wire | ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/03/2014 | 12:24PM | Business Wire | AP26113 d’ARIAD désigné par la FDA traitement révolutionnaire contre le cancer bronchique non à petites cellules ALK+ r... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 10/02/2014 | 7:35AM | Business Wire | ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 09/30/2014 | 10:18AM | Business Wire | ARIAD présente de nouveaux résultats de son étude clinique sur l'AP26113 chez des patients atteints d'un cancer du poumon ... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 09/29/2014 | 4:05PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 09/29/2014 | 7:35AM | Business Wire | ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 09/29/2014 | 7:35AM | Business Wire | ARIAD stellt aktualisierte klinische Ergebnisse zu AP26113 bei Patienten mit ALK-positivem nicht-kleinzelligem Lungenkrebs vor | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 09/18/2014 | 4:30PM | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 09/18/2014 | 4:06PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |